Artelo Biosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

EQUITY (Detail Narrative)

EQUITY (Detail Narrative) - USD ($)						1 Months Ended				12 Months Ended
EQUITY (Detail Narrative) - USD ($)	Mar. 05, 2024	Aug. 04, 2023	Feb. 02, 2023	Feb. 01, 2023	Jan. 06, 2023	Dec. 20, 2024	Feb. 29, 2024	Jan. 31, 2024	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Jan. 01, 2024	Jun. 01, 2023
Proceeds shares of common stock, value										$ 112,000	$ 567,000
Issued shares of common stock, shares										92,073	333,271
Preferred stock, par value										$ 0.001	$ 0.001
Preferred stock, shares authorized										416,667	416,667
Preferred stock, shares issued										0	0
Preferred stock, shares outstanding										0	0
Intrinsic value of the warrants										$ 0
Common stock, par value										$ 0.001	$ 0.001
Common stock, shares authorized										50,000,000	50,000,000
Common stock, shares issued										3,281,032	3,188,959
Common stock, shares outstanding										3,281,032	3,188,959
Issuance additional shares of common stock										425,344
Valuation [Member]
Options Granted										254,500	205,996
Option Granted, value										$ 307,000	$ 586,000
Stock-based compensation expense										818,000	1,020,000
Stock option expense, related parties										475,000	890,000
Stock option expense, unamortized										1,013,000
Stock option expense, unamortized, Related parties										652,000
Options Outstanding, intrinsic value										$ 0	$ 0
Valuation [Member] \| Related Parties [Member]
Options Granted										113,500	150,246
Option Granted, value										$ 137,000	$ 427,000
2018 Equity Incentive Plan [Member]
Common stock reserved for future issuance												478,344
Issuance additional shares of common stock					428,353
Common stock, shares issuable										1,529,223
Common stock, shares available to be issued										755,618			737,770
Options Granted In Fiscal Year Twenty Three [Member]
Exercise price		$ 2.01							$ 1.99
Granted options to purchase common stock		6,498							4,002
January, 2024 [Member] \| 2018 Equity Incentive Plan [Member]
Exercise price								$ 1.49
Granted options to purchase common stock								92,000
Vesting Percentage								25.00%
March 5, 2024 \| 2018 Equity Incentive Plan [Member]
Exercise price	$ 1.47
Granted options to purchase common stock	152,000
Vesting Percentage	25.00%
Febuary, 2024 \| Represents as a equity incentive plan.
Exercise price							$ 1.55
Options repriced							488,069
Additional amortization expense							$ 210,000
December 20, 2024 [Member] \| 2018 Equity Incentive Plan [Member]
Exercise price						$ 0.94
Granted options to purchase common stock						10,500
Vesting Percentage						100.00%
February One [Member] \| 2018 Equity Incentive Plan [Member]
Exercise price				$ 3.15
Granted options to purchase common stock				85,000
Vesting Percentage				25.00%
Febuary Two [Member] \| 2018 Equity Incentive Plan [Member]
Exercise price			$ 3.15
Granted options to purchase common stock			90,000
Vesting Percentage			25.00%
Febuary Two [Member] \| Equity Incentives Plan One [Member]
Exercise price			$ 3.15
Granted options to purchase common stock			19,750
Vesting Percentage			100.00%
Febuary Two [Member] \| Equity Incentives Plan Two [Member]
Exercise price			$ 3.15
Granted options to purchase common stock			746
Vesting Percentage			50.00%